How to buy Veracyte stock | $40.4

Veracyte, Inc is a biotechnology business based in the US. Veracyte shares (VCYT) are listed on the NASDAQ and all prices are listed in US Dollars. Veracyte employs 320 staff and has a trailing 12-month revenue of around 0.00.

Veracyte stock price (NASDAQ: VCYT)

Use our graph to track the performance of VCYT stocks over time.

Veracyte shares at a glance

• Key figures

Information last updated 2021-07-30.

Latest market close	$40.40
52-week range	$28.82 - $86.03
50-day moving average	$38.46
200-day moving average	$48.46
Wall St. target price	$65.14
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.29

Buy Veracyte shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Veracyte stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Veracyte, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Veracyte price performance over time

Historical closes compared with the close of $40.4 from 2021-05-26

1 week (2021-07-21)	N/A
1 month (2021-07-01)	0.90%
3 months (2021-04-30)	-18.79%
6 months (2021-01-28)	N/A

1 year (2020-07-28)	N/A
2 years (2019-07-28)	N/A
3 years (2018-07-28)	N/A
5 years (2016-07-28)	N/A

Veracyte financials

Revenue TTM	$123.1 million
Gross profit TTM	$77.1 million
Return on assets TTM	-3.03%
Return on equity TTM	-10.8%
Profit margin	-52.87%
Book value	$14.49
Market capitalisation	$2.6 billion

TTM: trailing 12 months

Shorting Veracyte shares

There are currently 3.9 million Veracyte shares held short by investors – that's known as Veracyte's "short interest". This figure is 9.6% down from 4.3 million last month.

There are a few different ways that this level of interest in shorting Veracyte shares can be evaluated.

Veracyte's "short interest ratio" (SIR)

Veracyte's "short interest ratio" (SIR) is the quantity of Veracyte shares currently shorted divided by the average quantity of Veracyte shares traded daily (recently around 796831.70731707). Veracyte's SIR currently stands at 4.92. In other words for every 100,000 Veracyte shares traded daily on the market, roughly 4920 shares are currently held short.

However Veracyte's short interest can also be evaluated against the total number of Veracyte shares, or, against the total number of tradable Veracyte shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Veracyte's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Veracyte shares in existence, roughly 60 shares are currently held short) or 0.0587% of the tradable shares (for every 100,000 tradable Veracyte shares, roughly 59 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Veracyte.

Find out more about how you can short Veracyte stock.

Veracyte share dividends

We're not expecting Veracyte to pay a dividend over the next 12 months.

Veracyte share price volatility

Over the last 12 months, Veracyte's shares have ranged in value from as little as $28.82 up to $86.03. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Veracyte's is 0.7318. This would suggest that Veracyte's shares are less volatile than average (for this exchange).

Veracyte overview

Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer diagnosis; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test that informs next steps for patients with early-stage breast cancer, as well as provides cancer subtype classification information. It is also developing nasal swab test for early lung cancer detection; Percepta Genomic Atlas for genomic profiling information on small samples of the tumor biopsy; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has biopharmaceutical collaborations with Johnson & Johnson; Acerta Pharma; Loxo Oncology, Inc. ; and Bayer AG.

Frequently asked questions

What percentage of Veracyte is owned by insiders or institutions?
Currently 1.014% of Veracyte shares are held by insiders and 106.03% by institutions. How many people work for Veracyte?
Latest data suggests 320 work at Veracyte. When does the fiscal year end for Veracyte?
Veracyte's fiscal year ends in December. Where is Veracyte based?
Veracyte's address is: 6000 Shoreline Court, South San Francisco, CA, United States, 94080 What is Veracyte's ISIN number?
Veracyte's international securities identification number is: US92337F1075 What is Veracyte's CUSIP number?
Veracyte's Committee on Uniform Securities Identification Procedures number is: 92337F107